Advanced search
Publication Cover
Future Virology Volume 7, 2012 - Issue 5
Submit an article Journal homepage
55
Views
0
CrossRef citations to date
0
Altmetric
Review

Predicting and Preventing Viral Escape from Therapy

Ben BerkhoutLaboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection & Immunity Amsterdam (CINIMA), Academic Medical Center (AMC), University of Amsterdam, Meibergdreef 15, K3–110, 1105AZAmsterdam, The Netherlands. [email protected]View further author information
Pages 483-487 | Published online: 17 May 2012

References

  • Berkhout B . HIV-1 evolution under pressure of protease inhibitors, climbing the stairs of viral fitness. J. Biomed. Sci.6 , 298–305 (1999).
  • Hache G , AbbinkTE, BerkhoutB, HarrisRS. Optimal translation initiation enables Vif-deficient human immunodeficiency virus type 1 to escape restriction by APOBEC3G. J. Virol.83(11) , 5956–5960 (2009).
  • Berkhout B . A new Houdini act: multiple routes for HIV-1 escape from RNAi-mediated inhibition. Future Microbiol.4(2) , 151–154 (2009).
  • Eggink D , BerkhoutB, SandersRW. Inhibition of HIV-1 by fusion inhibitors. Curr. Pharm. Des.16 , 3716–3728 (2010).
  • Ray N , BlackburnLA, DomsRW. HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide. J. Virol.83(7) , 2989–2995 (2009).
  • Baldwin CE , SandersRW, DengY et al. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J. Virol. 78(22) , 12428–12437 (2004).
  • Izumi K , KodamaE, ShimuraK et al. Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. J. Biol. Chem. 284(8) , 4914–4920 (2009).
  • Eggink D , LangedijkJP, BonvinAM et al. Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors. J. Biol. Chem. 284(39) , 26941–26950 (2009).
  • Dwyer JJ , WilsonKL, DavisonDK et al. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc. Natl Acad. Sci. USA 104(31) , 12772–12777 (2007).
  • Lefebvre E , SchifferCA. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev.10(3) , 131–142 (2008).
  • Zhou J , RossiJJ. Current progress in the development of RNAi-based therapeutics for HIV-1. Gene Ther.18(12) , 1134–1138 (2011).
  • Boden D , PuschO, LeeF, TuckerL, RamratnamB. Human immunodeficiency virus type 1 escape from RNA interference. J. Virol.77(21) , 11531–11535 (2003).
  • Das AT , BrummelkampTR, WesterhoutEM et al. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J. Virol. 78(5) , 2601–2605 (2004).
  • Westerhout EM , OomsM, VinkM, DasAT, BerkhoutB. HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res.33(2) , 796–804 (2005).
  • Ter Brake O , BerkhoutB. A novel approach for inhibition of HIV-1 by RNA interference: counteracting viral escape with a second generation of siRNAs. J. RNAi Gene Silencing1 , 56–65 (2005).
  • Schopman NC , Ter Brake O, Berkhout B. Anticipating and blocking HIV-1 escape by second generation antiviral shRNAs. Retrovirology7 , 52 (2010).
  • Nevot M , MartrusG, ClotetB, MartinezMA. RNA interference as a tool for exploring HIV-1 robustness. J. Mol. Biol.413(1) , 84–96 (2011).
  • Ter Brake O , von Eije KJ, Berkhout B. Probing the sequence space available for HIV-1 evolution. AIDS22(14) , 1875–1877 (2008).
  • Ter Brake O , BerkhoutB. Lentiviral vectors that carry anti-HIV shRNAs: problems and solutions. J. Gene Med.9(9) , 743–750 (2007).
  • Schopman NC , BraunA, BerkhoutB. Directed HIV-1 evolution of protease inhibitor resistance by second-generation short hairpin RNAs. Antimicrob. Agents Chemother.56(1) , 479–486 (2012).
  • Perrin V , MammanoF. Parameters driving the selection of nelfinavir-resistant human immunodeficiency virus type 1 variants. J. Virol.77(18) , 10172–10175 (2003).
  • Burnett JC , RossiJJ. RNA-based therapeutics: current progress and future prospects. Chem. Biol.19(1) , 60–71 (2012).
  • Bushman FD , MalaniN, FernandesJ et al. Host cell factors in HIV replication: meta-analysis of genome-wide studies. PLoS Pathog. 5(5) , e1000437 (2009).
  • Eekels JJM , BerkhoutB. Towards a durable treatment of HIV-1 infection using RNA interference. Prog. Mol. Biol. Transl. Sci.102 , 141–163 (2011).
  • Agrawal-Gamse C , LeeFH, HaggartyB et al. Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4. J. Virol. 83(21) , 11005–11015 (2009).
  • Westby M , Smith-BurchnellC, MoriJ et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81(5) , 2359–2371 (2007).
  • Nedellec R , CoetzerM, LedermanMM et al. Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use. PLoS One 6(7) , e22020 (2011).
  • Liu R , PaxtonWA, ChoeS et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86(3) , 367–377 (1996).
  • Ogg GS , JinX, BonhoefferS et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279(5359) , 2103–2106 (1998).
  • Goulder PJ , WatkinsDI. HIV and SIV CTL escape: implications for vaccine design. Nat. Rev. Immunol.4(8) , 630–640 (2004).
  • Brumme ZL , JohnM, CarlsonJM et al. HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PloS One 4(8) , e6687 (2009).
  • Martinez-Picado J , PradoJG, FryEE et al. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J. Virol. 80(7) , 3617–3623 (2006).
  • Sturmer M , DoerrHW, GurtlerL. Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus. Med.Microbiol. Immunol.198(3) , 147–155 (2009).
  • Pan Q , TilanusHW, JanssenHL, van der Laan LJ. Prospects of RNAi and microRNA-based therapies for hepatitis C. Expert. Opin.Biol. Ther.9(6) , 713–724 (2009).
  • Soriano V , VispoE, PovedaE et al. Directly acting antivirals against hepatitis C virus. J. Antimicrob. Chemother. 66(8) , 1673–1686 (2011).
  • Ivacik D , ElyA, ArbuthnotP. Countering hepatitis B virus infection using RNAi: how far are we from the clinic? Rev. Med. Virol.21(6) , 383–396 (2011).
  • Berkhout B . Toward a durable anti-HIV gene therapy based on RNA interference. Ann. NY Acad. Sci.1175 , 3–14 (2009).
  • Allers K , HutterG, HofmannJ et al. Evidence for the cure of HIV infection by CCR5-delta32/delta32 stem cell transplantation. Blood 117 , 2791–2799 (2010).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.